autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4+/cd8+ central memory t-lymphocytes jcar014
Cell therapyexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 15, 2016 (NCT02706405)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4+/cd8+ central memory t-lymphocytes jcar014
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02706405 | Phase 1 | Nov 15, 2016 | AstraZeneca, Juno Therapeutics, Inc., MedImmune, National Cancer Institute (NCI), University of Washington |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 1 | 0 | 1 | 2016 |
| Juno Therapeutics, Inc. | For profit | 1 | 0 | 1 | 2016 |
| MedImmune | For profit | 1 | 0 | 1 | 2016 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2016 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2016 |
5 organizations
Page 1 / 1